Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® in previously treated advanced melanoma
Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma
KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma
Silver Hammer Announces Uplisting to the OTCQB Venture Market in the United States, and Receives DTC Eligibility
